Share on networks
The German company Merck has invested 14.5 million euros in its facilities in Mollet del Vallès (Barcelona). This large investment will meet increased demand for the company’s specific products in its Life Sciences sector, such as the production of some Covid-19 vaccines.
The expansion project is a further demonstration of the Merck Group’s commitment to its operations in Catalonia while reinforcing its commitment to international supply solutions at this site, as production from the new building will be exported around the world.
Miguel Fernández Alcalde, Managing Director of Merck in Spain, said: “In the last 4 years Merck has invested a total of 90 million euros in the Mollet del Vallès site and in the biotechnology plant in Tres Cantos (Madrid). This has had a clear impact on our production and export capacity from Spain. Specifically, around 99% of the production developed at the Mollet del Vallès site is exported to other countries”.